AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32522106
Drug: 5-fluorouracil/leucovorin (5-FU/LV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/leucovorin (5-FU/LV) chemotherapy
Trial: 33296079
Drug: High-protein enteral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein enteral nutrition (63 or 100 g/L protein) for ≤28 days
Trial: 33296079
Drug: Usual practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual practice enteral nutrition (lower protein doses)
Trial: 34421925
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies
Trial: 33043969
Drug: Vesatolimod (1-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesatolimod (1-12 mg)
Trial: 33043969
Drug: Vesatolimod (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesatolimod (6 mg)
Trial: 32721009
Drug: Intravenous acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen, 1 g, starting at the beginning of surgery and repeated every 6 hours until 48 postoperative hours or hospital discharge
Trial: 35873893
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C infusion (1.5 g/6 h for 4 days)
Trial: 35873893
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (100 mg vitamin C/day for 4 days)
Trial: 33177370
Drug: Attention Control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Control (video on a tablet)
Trial: 34578862
Drug: 1-Kestose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-Kestose supplementation (10 g/day for 12 weeks)
Trial: 33226202
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (120 kVp and standard weight‐adapted CM dose)
Trial: 39489284
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily step count
Trial: 35172871
Drug: HSM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSM plus original antihypertensive regimen
Trial: 35172871
Drug: Control (original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (original antihypertensive regimen only)
Trial: 34462279
Drug: Levonorgestrel 52
RxNorm normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52 mg intrauterine system (LNG‐IUS 52 mg)
Trial: 32652300
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (40 mg for 14 days) + Metformin (1000 mg daily for 3 months)
Trial: 32652300
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (40 mg for 14 days) + Placebo
Trial: 32148744
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation with video-game based therapy for 8 weeks, 5 sessions per week
Trial: 34757164
Drug: LAVmax >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAVmax > 22.1 mL/m1.72
Trial: 33245533
Drug: tamsulosin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin + mirabegron 50 mg
Trial: 34743348
Drug: FPC 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPC 6.75 mg Fe IV predialyzer
Trial: 34743348
Drug: FPC 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPC 6.75 mg Fe IV postdialyzer
Trial: 34743348
Drug: FPC 2
RxNorm normalized name: FPC
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FPC 2 μM (110 μg Fe/L of hemodialysate)
Trial: 34743348
Drug: FPC IV
RxNorm normalized name: FPC
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FPC IV infusion of 6.75 mg iron during 3 hours of HD
Trial: 34092587
Drug: Fascial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial treatment (FT)
Trial: 35688442
Drug: HTX‐011 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX‐011 (400 mg bupivacaine/12 mg meloxicam) with multimodal analgesic regimen (preoperative acetaminophen, celecoxib, pregabalin, and postoperative acetaminophen and celecoxib)
Trial: 33164410
Drug: Xiaoji Recipe
RxNorm normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoji Recipe + Rosuvastatin Calcium 10 mg·d(‐1)
Trial: 33164410
Drug: Rosuvastatin Calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin Calcium 20 mg·d(‐1)
Trial: 34783626
Drug: Blended Rational
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Rational Emotive Behavior Therapy (REBT) for 12 weeks (2 hours weekly)
Trial: 35723940
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide 35% solution
Trial: 34865318
Drug: Acyclovir nanofiber
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir nanofiber patch
Trial: 34865318
Drug: Placebo nanofiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nanofiber patch
Trial: 615706097
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (EMLA)
Trial: 615706097
Drug: Placebo (moisturising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (moisturising cream)
Trial: 33403727
Drug: Ciclesonide inhalation
RxNorm normalized name: Ciclesonide Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide inhalation (343 µg/actuation) solution
Trial: 33403727
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 µg/actuation)
Trial: 36222067
Drug: Integrated smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated smoking cessation treatment
Trial: 36146946
Drug: Guarana (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guarana (125 mg/kg)
Trial: 36146946
Drug: Placebo (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (65 mg/kg protein powder)
Trial: 34537120
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg.kg‐1. h‐1 (Group D)
Trial: 34537120
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 15 mg.kg‐1. h‐1 (Group M)
Trial: 34875106
Drug: Antipsychotic monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic monotherapy
Trial: 32649925
Drug: Antipsychotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics plus psychological intervention
Trial: 34521466
Drug: Lycium barbarum
RxNorm normalized name: LYCIUM BARBARUM FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycium barbarum polysaccharide (LBP) supplementation capsules
Trial: 34521466
Drug: Maltodextrin placebo
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin placebo capsules
Trial: 616081502
Drug: topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical 0.1% fluorometholone
Trial: 32621467
Drug: Lornoxicam (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (16 mg/day for 2 days)
Trial: 32621467
Drug: Xefocam (lyophilisate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xefocam (lyophilisate for preparation of solution for intravenous and intramuscular injection)
Trial: 32553589
Drug: Non-surgical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical management (NSM) including radiation therapy (71% of NSM), hormonal therapy (25% of NSM), and both (4% of NSM)
Trial: 35867804
Drug: istaroxime 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: istaroxime 1.0 - 1.5 μg/kg/min
Trial: 35656943
Drug: Pfizer-BioNTech COVID-19
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech COVID-19 vaccine
Trial: 35317850
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) injection to the vocal cord contralateral to the lesion
Trial: 34971304
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of bupivacaine (3 mL of 0.5% plain bupivacaine hydrochloride)
Trial: 34934307
Drug: Esmolol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 0.5 mg/kg for 5 min before anesthesia induction, maintained at 0.5 mg/kg/h
Trial: 34934307
Drug: Esmolol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.0 mg/kg for 5 min before anesthesia induction, maintained at 2.0 mg/kg/h
Trial: 34934307
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.75 mL/kg/h for 5 min before anesthesia induction, maintained at 0.25 mL/kg/h
Trial: 34569486
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg/day)
Trial: 34569486
Drug: Rituximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (500 mg/m2 + 2 for 6 cycles)
Trial: 32126750
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of propofol (CI group)
Trial: 32126750
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injection of propofol (BI group)
Trial: 35534494
Drug: Prednisolone 1
RxNorm normalized name: prednisolone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1 mg/kg/day (max 60 mg/day) alone
Trial: 35534494
Drug: Prednisolone 1
RxNorm normalized name: prednisolone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1 mg/kg/day (max 60 mg/day) with methotrexate 0.3 mg/kg/week for 9 months
Trial: 33908665
Drug: Nicotine mini-lozenge
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mini-lozenge
Trial: 33908665
Drug: Nicotine mini-lozenge
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mini-lozenge + Reduction counseling
Trial: 34757134
Drug: Probiotic formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formula (Lactobacillus acidophilus LA‐5, Lactobacillus plantarum, Bifidobacterium lactis BB‐12, Saccharomyces boulardii) administered as two sachets twice daily for 15 days
Trial: 33050928
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg administered subcutaneously every 4 weeks
Trial: 33743799
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (1 unit, 200-399 mL)
Trial: 35900726
Drug: Talazoparib, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib, 1 mg orally daily and avelumab, 10 mg/kg intravenously every 2 weeks
Trial: 38942209
Drug: Cariprazine 3-12
RxNorm normalized name: cariprazine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 3-12 mg/d
Trial: 34418399
Drug: Non-immunogenic staphylokinase
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-immunogenic staphylokinase (10 mg)
Trial: 34418399
Drug: Alteplase (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (0.9 mg/kg, maximum 90 mg)
Trial: 33141078
Drug: Aquatic exercises
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic exercises (16 weeks, twice per week, 45 min/session)
Trial: 33952398
Drug: SDS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDS group (subcutaneous sufentanil and dexmedetomidine)
Trial: 33952398
Drug: SDI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDI group (intravenous sufentanil and dexmedetomidine)
Trial: 33952398
Drug: SS group
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS group (subcutaneous sufentanil)
Trial: 33952398
Drug: SI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SI group (intravenous sufentanil)
Trial: 35799113
Drug: Potentially Inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially Inappropriate Medications (PIMs)
Trial: 33452350
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) (propofol/remifentanil)
Trial: 34910219
Drug: Second 1-g
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second 1-g TXA
Trial: 36059420
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of apatinib
Trial: 32542334
Drug: Novel botanical
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel botanical formula (6 mg, 10 mg, or 14 mg of lutein)
Trial: 32542334
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein formula
Trial: 32542334
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg lutein formula
Trial: 32542334
Drug: Novel botanical
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel botanical formula (all doses)
Trial: 36217243
Drug: Systemic congruence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic congruence couple therapy (CCT)
Trial: 36217243
Drug: Individual-based treatment-as-usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-based treatment-as-usual (TAU)
Trial: 34780099
Drug: CAMS‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMS‐G
Trial: 36252151
Drug: Formula C
RxNorm normalized name: Stress Formula Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula C (cannabidiol-rich preparation)
Trial: 35428274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (education about clinical manifestations, risk factors, diagnosis, treatment, and nursing care for knee via printed materials)
Trial: 32359094
Drug: Low skeletal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low skeletal muscle index (myopenia), high intramuscular adipose tissue content (myosteatosis), and high visceral to subcutaneous adipose tissue area (adiposity)
Trial: 32284380
Drug: Durlobactam (DUR)
RxNorm normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durlobactam (DUR) 1 g
Trial: 32284380
Drug: Durlobactam (DUR)
RxNorm normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durlobactam (DUR) 0.25 to 8 g (single ascending doses)
Trial: 32284380
Drug: Durlobactam (DUR)
RxNorm normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durlobactam (DUR) 0.25 to 2 g (multiple ascending doses every 6 hours for 29 doses)
Trial: 32284380
Drug: Durlobactam (DUR)
RxNorm normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durlobactam (DUR) 1 g with SUL (1 g) and/or IMI-CIL (0.5/0.5 g)
Trial: 35066737
Drug: Carvedilol-IR twice
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol-IR twice a day
Trial: 32503608
Drug: YinQiSanHuang-antiviral decoction
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: YinQiSanHuang-antiviral decoction with entecavir
Trial: 34295663
Drug: Docetaxel (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (37.5 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (DC group)
Trial: 34295663
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (GC group)
Trial: 34295663
Drug: Previous literature
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous literature anti-tumor therapy only group
Trial: 32325794
Drug: Lactobacilli (L.)
RxNorm normalized name: lactobacillic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli (L.) rhamnosus GR‐1 and L. reuteri RC‐14, 5 × 10^9 CFU, 2 capsules/day for 2 months
Trial: 32325794
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (both groups)
Trial: 33376176
Drug: Adjunct oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct oral betamethasone for 2 days
Trial: 32019557
Drug: Fluid restriction
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid restriction + low CVP (Group L)
Trial: 32220375
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of pre-operative bowel preparation
Trial: 35792365
Drug: Liraglutide 1.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.80 mg
Trial: 32003275
Drug: Medication Adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Adherence and Care Engagement (MACE)
Trial: 33813569
Drug: Sugammadex 1
RxNorm normalized name: sugammadex 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 1 mg/kg
Trial: 35750637
Drug: AdVEGF‐D gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdVEGF‐D gene therapy
Trial: 32681063
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (recorded maternal singing/heartbeat)
Trial: 34405233
Drug: Early-onset stage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-onset stage III colon adenocarcinoma (EO-CC)
Trial: 35618953
Drug: Reparixin 1200
RxNorm normalized name: Réparixine
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparixin 1200 mg orally three times daily for up to 21 days
Trial: 33621540
Drug: NT-proBNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP plasma concentrations ≤400 pg/mL
Trial: 33621540
Drug: NT-proBNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP plasma concentrations 400-999 pg/mL
Trial: 33621540
Drug: NT-proBNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP plasma concentrations 1000-1999 pg/mL
Trial: 33621540
Drug: NT-proBNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP plasma concentrations 2000-2999 pg/mL
Trial: 33621540
Drug: NT-proBNP plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP plasma concentrations ≥3000 pg/mL
Trial: 33048053
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy (Control)
Trial: 35352280
Drug: Erlotinib 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 75 mg QD plus ritonavir 200 mg QD
Trial: 35352280
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg QD (control arm)
Trial: 32423463
Drug: Interprofessional collaboration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interprofessional collaboration concept involving GPs in regional teams with on-call schedules, pre-weekend visits, joint meetings, documentation, and improved medication safety.
Trial: 32423463
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receives treatment as usual.
Trial: 36157118
Drug: Anti-bacterial antibody
RxNorm normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-bacterial antibody responses in CD patients
Trial: 36157118
Drug: Anti-bacterial antibody
RxNorm normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-bacterial antibody responses in healthy controls